Anbio Biotechnology Class A Ordinary Shares (NNNN) Stock Price & Analysis
Anbio Biotechnology Class A Ordinary Shares (NNNN) — MoonshotScore 55/100 (Fair band), calculated Nov 18, 2026. Price $3.32 (-9.04%), as of the Nov 20, 2026 trading session; market cap $146M.
Educational signal · not a buy or sell recommendation · How to read this
Anbio Biotechnology Class A Ordinary Shares · NNNN · NASDAQ
Anbio Biotechnology focuses on in vitro diagnostics (IVD) across global markets. They offer a range of diagnostic tests and products, serving over-the-counter, point-of-care testing, and laboratory markets.
Price as of Nov 20, 2026
Key Statistics
MoonshotScore v2 · Anbio Biotechnology Class A Ordinary Shares (NNNN)
FairWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Elite quality, a strong balance sheet and durable growth, but a full valuation, and the price trend has turned against it. The score also carries a risk penalty for reported profit not backed by cash flow. Business Quality: Elite; Financial Safety: Fortress; Valuation: Full; Growth Durability: Growing; Momentum: Falling.
- quarterly revenue $5M (Q4 FY2025, quarter ended Dec 31, 2025)
- ROE 27.0% · ROA 14.7%
Holding back: weak price trend
Helping: business quality, balance-sheet strength, durable growth
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 56 | Fair | |
| 55 | Fair | |
| 55 | Fair | |
| 55 | Fair | |
| 55 | Fair | |
| 55 | Fair |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $3.32 | |
| Change on the day | -9.04% | |
| 52-week range | $3.09 – $44.73 | |
| Market capitalisation | $146M | — |
| Price / earnings (trailing) | 18.87 | |
| Shares traded on the day | 79.5K |
Price & events
Other perspectives
Council score for Anbio Biotechnology Class A Ordinary Shares (NNNN): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
5 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 19, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 19, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Nov 19, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 21, 2026, except a card that shows its own read date.
What is Anbio Biotechnology Class A Ordinary Shares (NNNN), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Anbio Biotechnology Class A Ordinary Shares (NNNN) is listed on NASDAQ. It employs 27 people and is led by Michael Lau. In Q4 FY2025 it reported revenue of $5M and net income of $3M. The market values it at $146M.
What do the latest results show for Anbio Biotechnology Class A Ordinary Shares (NNNN)?
Short answer · as of
The most recent reported quarter, Q4 FY2025, carried revenue of $5M.
Quarterly income statement — 3 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q4 FY2025 | $5M | $3M | $0.07 (diluted) |
| Q3 FY2025 | $2M | $1M | $0.03 (diluted) |
| Q2 FY2025 | $5M | $4M | $0.09 (diluted) |
What are the financial strengths and risks for Anbio Biotechnology Class A Ordinary Shares (NNNN)?
Short answer
The MoonshotScore pillars rate business quality, balance-sheet strength, durable growth as strengths. What is holding it back is weak price trend. The distress and quality screens read Piotroski F 3. Trailing ratios: ROE 27.0% · ROA 14.7%.
How does Anbio Biotechnology Class A Ordinary Shares compare with its peers?
Short answer
Anbio Biotechnology Class A Ordinary Shares's score ranks 4th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $69.49 Nov 20, 2026 | $198M | 87 5-pillar Nov 18, 2026 | |
| $63.49 Nov 19, 2026 | $203M | 87 5-pillar Nov 18, 2026 | |
| $14.35 Nov 20, 2026 | $287M | 85 5-pillar Nov 18, 2026 | |
| Anbio Biotechnology Class A Ordinary Shares (NNNN) — this page | $3.32 | $146M | 55 |
| $7.45 Nov 20, 2026 | $43.5M | 47 5-pillar Nov 18, 2026 | |
| $3.38 Nov 20, 2026 | $538M | 41 5-pillar Nov 18, 2026 | |
| $32.67 Nov 19, 2026 | $300M | 39 5-pillar Nov 18, 2026 | |
| $4.07 Nov 19, 2026 | $44.8M | 39 5-pillar Nov 18, 2026 | |
| $10.81 Nov 20, 2026 | $455M | 37 5-pillar Nov 18, 2026 | |
| $3.46 Nov 20, 2026 | $239M | 35 5-pillar Nov 18, 2026 | |
| $0.68 Nov 20, 2026 | $45.7M | 30 5-pillar Nov 18, 2026 | |
| $8.66 Nov 20, 2026 | $39.6M | 26 5-pillar Nov 18, 2026 | |
| $8.32 Nov 20, 2026 | $571M | 25 5-pillar Nov 18, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held NNNN in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported NNNN in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
Common Questions About NNNN
These answers are editorial: 1 of these 9 answers is drawn from the NNNN research dossier (written May 9, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for NNNN?
NNNN carries the MoonshotScore stated above — the Fair band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. Anbio Biotechnology focuses on in vitro diagnostics (IVD) across global markets.
Is NNNN a good stock to buy?
Stock Expert AI does not rate NNNN buy, sell or hold. Anbio Biotechnology Class A Ordinary Shares carries a MoonshotScore, in the Fair band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the NNNN stock price today?
The last price recorded for Anbio Biotechnology Class A Ordinary Shares (NNNN), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What are the main risks for NNNN?
Anbio Biotechnology faces several risks, including intense competition from established IVD companies, regulatory changes and compliance requirements, and economic downturns affecting healthcare spending.
What are the key factors to evaluate for NNNN?
Anbio Biotechnology Class A Ordinary Shares (NNNN) holds a MoonshotScore in the moderate range. To weigh it, start with the trailing P/E under Price & valuation on this page. By establishing strategic partnerships and distribution networks in these markets, Anbio can increase its market share and revenue streams. Not financial advice.
How frequently does NNNN data refresh on this page?
NNNN's price is the last quote we recorded, from the Nov 20, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven NNNN's recent stock price performance?
Anbio Biotechnology Class A Ordinary Shares (NNNN) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diverse product portfolio of IVD tests. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider NNNN overvalued or undervalued right now?
The trailing P/E of Anbio Biotechnology Class A Ordinary Shares (NNNN) is listed under Price & valuation on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of NNNN?
Fractional-share availability for Anbio Biotechnology Class A Ordinary Shares (NNNN) depends on your brokerage, account and supported securities. Check the broker's current eligibility, minimums and fees before placing an order.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 9, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 15 figures on this page — 8 from Financial Modeling Prep (FMP), 6 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com